Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (468)	1/22/2000 10:06:00 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 1834

I agree with your comments that one should really question whether one should sell at all when a strong winner is found. After further and continued analysis of NBIX, there is a solid chance for two or three marketed drugs, if not more. My model does not provide any significant value to the MS program, compared to that of the CNS tumor program, the sedative program or the depression program. I guess these boards (ie certain individuals' philosophies) help push the concept that one should take profits, and take them early sometimes in volatile sectors. You never go broke taking a profit is the phrase commonly used. However, in my twelve or so years in the market, I could kick myself for trading out of QCOM, AMGN, INTC and MSFT. Especially the first two, when I was in early and had two to four baggers. In the current tech, biotech and oil drillers rally, I have forced myself to let the profits ride. Having said all this, I believe we have another QCOM here in the making. We may see some profit taking in the near term, especially if the other techs correct. To me that will represent an additional NBIX buying opportunity. By the way, do you think that the recent action in REGN is simply profit taking? As you know, this is a company that I have faith in. It is another of my long term holds in the biotechs. Another favorite is SEPR, which is also quite strong here.